Other languages Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
3.68 ^USD	+1.38%		-4.42%	-35.78%

04-05	Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	MT
04-04	Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	04-05
Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients	04-04
Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	04-04
50 valores para invertir en IA, salud, movilidad y energía	03-25
50 aandelen om te beleggen in KI, gezondheid, mobiliteit en energie	03-23
50 titoli per investire in AI, salute, mobilità ed energia	03-22
50 Top-Aktien für Investitionen in KI, Gesundheit, Mobilität und Energie	03-22
50 valeurs pour investir dans l'IA, la Santé, la Mobilité et l'Energie	03-22
Caribou Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-11
Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer	01-07
Caribou Biosciences Says it Reached Alignment With FDA on Phase 3 Trial Plan for Lymphoma Treatment	12-13
MORNING BRIEFING - USA/Asien	12-13
Syed Rizvi to Leave the Caribou Biosciences, Inc. as Chief Medical Officer, Effective from December 31, 2023	12-12
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024	12-12
Caribou Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
Caribou Biosciences, Inc. Appoints Sundar Jagannath to its Scientific Advisory Board	11-06
US FDA Clears Caribou Biosciences' CB-012 Cancer Drug Candidate for Human Study	18/10/23
Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	18/10/23
Caribou Biosciences, Inc. Appoints Reigin Zawadzki as Chief People Officer	27/09/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Other languages

Filters